Innova Biosciences signs out-licensing deal with StressMarq Biosciences
Innova Biosciences , inventor of the world’s easiest to use bioconjugation kits, is pleased to announce that the company has entered into a licensing agreement with StressMarq Biosciences (British Columbia, Canada).
Online PR News – 27-September-2012 –Innova Biosciences (Cambridge, UK), inventor of the world’s easiest to use bioconjugation kits, is pleased to announce that the company has entered into a licensing agreement with StressMarq Biosciences (British Columbia, Canada).
The non-exclusive license will allow StressMarq to use Innova’s unique Lightning-Link® technology for commercial purposes. Through the commercialisation deal, StressMarq will create a novel collection of antibody conjugate research tools for the scientific community, with the ultimate objective being the advancement of pioneering science and to elucidate the molecular abnormalities behind disease states such as cancer or diabetes.
Dr Andy Lane, Licensing Manager at Innova Biosciences, said, “This agreement underlines the attractiveness of the Lightning-Link® technology to specialist antibody companies, who can take advantage of the simplicity of the method combined with 100% yields to rapidly increase their catalogue portfolios. We look forward to working with StressMarq, who have an excellent reputation in the research antibody sector.”
Commenting on the agreement StressMarq’s President, Dr Ariel Louwrier, said, “The unique aspects of the Lightning-Link® technology coupled with the core expertise of StressMarq Biosciences in the heat shock protein, cellular stress, ion channels and transporter areas will allow us to better serve the needs of our customers, covering a whole new host of applications. The demonstrated and proven Lightning-Link® technology is an excellent counterpart to our antibody portfolio.”
About Innova Biosciences Limited;
About StressMarq Biosciences;
Copyright 2014 Online PR Media | PO Box 5043 | La Quinta, CA 92248